MINOCA‐BAT 2021.

Study name	Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients
Methods	Multi‐national, multi‐centre, pragmatic randomised clinical trial
Participants	Patients > 18 years of age with clinical diagnosis of MINOCA within the last 30 days, left ventricular ejection fraction ≥ 40% measured with echocardiography, MRI or left ventriculography after admission and before randomisation
Interventions	Experimental: beta‐blocker and ACEI/ARB Experimental: beta‐blocker alone Experimental: ACEI/ARB alone No intervention: no beta‐blocker and no ACEI/ARB
Outcomes	Primary outcomes • Time to death of any cause • Time to re‐admission because of AMI, ischaemic stroke, or heart failure Secondary outcomes • All‐cause death • Cardiovascular death • Re‐admission because of AMI • Re‐admission because of ischaemic stroke • Re‐admission because of heart failure • Re‐admission because of unstable angina pectoris • Re‐admission because of atrial fibrillation
Starting date	16 December 2018
Contact information	Terese Karlin, MSc Pharm; +46 18 617 04 36; terese.karlin@ucr.uu.se
Notes	Estimated study completion date: 1 October 2025 NCT number: NCT03686696